Nexavar

Phase 3Small molecule

Bayer

Nexavar is one of 257 small molecule programs targeting Liver Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

256

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Chronic Myelogenous LeukemiaActive, not recruiting

Neurofibromatosis Type 1Active, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Thyroid CancerActive, not recruiting

Liver TransplantPhase 1

Active, not recruiting

Chronic Myelogenous LeukemiaPhase 2

Active, not recruiting

Neurofibromatosis Type 1Phase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 3

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Thyroid CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 3

1 2

Trodelvy

Gilead

Preclinical

37 3

Tykerb

GSK

Preclinical

80 4

Avastin

Spravato

2 6

Avastin

Roche

Preclinical

4 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—9

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 10

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Renal Cell Carcinoma5 trials

Research Study for Patients With Metastatic Renal Cell Carcinoma

Terminated· Bayer logo

Bayer·Phase 2·NCT00110344·1 enrolled

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Completed· Bayer logo

Bayer·Phase 3·NCT00492986·1,150 enrolled

BAY43-9006 Phase II Study for Renal Cell Carcinoma

Completed· Bayer logo

Bayer·Phase 2·NCT00661375·131 enrolled

Show 2 more trials

Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)

Completed·IItalian Trial in Medical Oncology·Phase 2·NCT00609401·90 enrolled

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Completed· Bayer logo

Bayer··NCT00895674·2,840 enrolled

Sorafenib2 trials

Bioequivalence Study of Sorafenib Tablet and Nexavar

Completed·YYabao Pharmaceutical Group·Phase 1·NCT02599337·36 enrolled

A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers

Completed·DDisruptive Pharma·Phase 1·NCT06797427·12 enrolled

Thyroid Cancer1 trial

Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

Completed·FFujian Medical University·Phase 2·NCT03565536·18 enrolled

Hepatocellular Carcinoma1 trial

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

Completed· Bayer logo

Bayer·Phase 3·NCT00692770·1,114 enrolled

Neurofibromatosis Type 11 trial

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00727233·9 enrolled

8 more indications

Doxorubicin1 trial

Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin

Completed· Bayer logo

Bayer·Phase 1·NCT00562913·21 enrolled

Breast Cancer1 trial

Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 2·NCT00548899·36 enrolled

Chronic Myelogenous Leukemia1 trial

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec

Completed· Bayer logo

Bayer·Phase 2·NCT00661180·10 enrolled

Non-Small Cell Lung Cancer1 trial

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

Completed· Bayer logo

Bayer·Phase 1·NCT01069328·33 enrolled

Patients With Solid Tumors1 trial

Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

Completed· Bayer logo

Bayer·Phase 1·NCT00606125·16 enrolled

Biomarkers1 trial

Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients

Terminated·MMedical University Innsbruck··NCT01507740·60 enrolled

Liver Transplant1 trial

Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)

Terminated·—·Phase 1·NCT01337492·2 enrolled

Unspecified1 trial

Extension Program for Bay 43-9006

Completed· Bayer logo

Bayer·Phase 2·NCT00657254·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Nexavar. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nexavar compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nexavar. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Nexavar

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Renal Cell Carcinoma5 trials

Sorafenib2 trials

Thyroid Cancer1 trial

Hepatocellular Carcinoma1 trial

Neurofibromatosis Type 11 trial

Doxorubicin1 trial

Breast Cancer1 trial

Chronic Myelogenous Leukemia1 trial

Non-Small Cell Lung Cancer1 trial

Patients With Solid Tumors1 trial

Biomarkers1 trial

Liver Transplant1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News